These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30078116)

  • 1. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
    Tran AN; Sachdev R; Fricker ZP; Leber M; Zahorian T; Shah B; Nunes DP; Long MT
    Dig Dis Sci; 2018 Dec; 63(12):3241-3249. PubMed ID: 30078116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals.
    Zhu J; Hazen RJ; Joyce C; Delpino A; Kirkham HS; Strickland CD; Markes-Wilson S; Kim T; Kang M; Rubin RA; Stein LL
    J Am Pharm Assoc (2003); 2018; 58(1):89-93.e2. PubMed ID: 29154019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
    Yang S; Britt RB; Hashem MG; Brown JN
    J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Marshall MC; Herrera JL
    Dig Dis Sci; 2018 Dec; 63(12):3228-3232. PubMed ID: 30128645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
    Stewart RA; MacDonald BR; Chu TC; Moore JD; Fasanmi EO; Ojha RP
    Dig Dis Sci; 2018 Dec; 63(12):3233-3240. PubMed ID: 30014226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response from hepatitis C from an emergency department screening & linkage program: A retrospective review.
    Walter LA; Wilson L; Farmer M; Roberson T; Hand DT; Franco R
    Am J Emerg Med; 2023 Oct; 72():178-182. PubMed ID: 37540919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
    J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
    JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
    Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
    BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
    Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
    J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
    Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
    Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Sikavi C; Najarian L; Saab S
    Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.